cardiovascular system
N |
• surprisingly, untreated homozygotes are viable and fertile and do not display any embryonic or early postnatal defects in vascular development
• overall morphology and density of the retinal vasculature is normal at P7
• similarly, neonatal tracheal blood vasculature and tracheal lymphatic vessels appear normal
|
• after treatment with anti-BMP10, neonatal homozygotes show a disorganized tracheal blood vasculature, unlike similarly treated wild-type controls
|
• after treatment with anti-BMP10 monoclonal antibody from P2 through P7, neonatal homozygotes display abnormal retinal vasculature, unlike similarly treated wild-type controls
• after treatment with anti-BMP10, retinal vascular density is markedly increased
|
• after treatment with anti-BMP10, affected retinal blood vessels show reduced coverage of alphaSMA-positive mural cells
|
• after treatment with anti-BMP10, expansion of the vascular plexus in the nerve fiber layer from the optic nerve head (ONH) is markedly delayed
|
immune system
• after treatment with anti-BMP10, P7 tracheal lymphatic vessels appear highly irregular
|
• after treatment with anti-BMP10, P7 tracheal lymphatic vessels appear dilated
|
vision/eye
• after treatment with anti-BMP10 monoclonal antibody from P2 through P7, neonatal homozygotes display abnormal retinal vasculature, unlike similarly treated wild-type controls
• after treatment with anti-BMP10, retinal vascular density is markedly increased
|
• after treatment with anti-BMP10, affected retinal blood vessels show reduced coverage of alphaSMA-positive mural cells
|
• after treatment with anti-BMP10, expansion of the vascular plexus in the nerve fiber layer from the optic nerve head (ONH) is markedly delayed
|